Financial Performance - The company's operating revenue for Q1 2022 was ¥81,372,982.62, representing a 1.07% increase compared to ¥80,512,287.36 in the same period last year[3] - Net profit attributable to shareholders decreased by 20.19% to ¥9,026,615.21 from ¥11,309,433.07 year-on-year[3] - The net profit after deducting non-recurring gains and losses fell by 31.28% to ¥6,863,477.89, primarily due to increased procurement costs[7] - Basic and diluted earnings per share decreased by 23.08% to ¥0.20, reflecting the decline in net profit[3] - Operating profit decreased to ¥9,858,640.28 from ¥13,048,847.76, a decline of 24.67%[19] - Net profit for Q1 2022 was ¥9,026,732.54, down 20.16% from ¥11,309,433.07 in the same period last year[20] Cash Flow and Expenses - The net cash flow from operating activities dropped by 157.79% to -¥3,677,645.24, attributed to higher procurement expenses and increased R&D investments[7] - Cash flow from operating activities showed a net outflow of ¥3,677,645.24, compared to a net inflow of ¥6,364,105.62 in Q1 2021[22] - The net cash flow from investment activities was negative at ¥-16,142,565.39, down from a positive cash flow of ¥25,246,852.30 in the same period last year[24] - Research and development expenses increased to ¥7,043,416.03 from ¥4,239,384.96, marking a rise of 66.5%[18] Assets and Liabilities - Total assets increased by 89.62% to ¥1,530,805,737.72, mainly due to funds raised from the public issuance of A-shares[7] - The company's total liabilities amounted to CNY 357.18 million, up from CNY 337.85 million, indicating a rise of approximately 5.4%[17] - The company's cash and cash equivalents increased to CNY 1,049.81 million from CNY 345.66 million, representing a growth of about 203.5%[15] - The company reported accounts receivable of CNY 39.23 million, an increase from CNY 32.03 million, representing a growth of approximately 22.6%[15] Shareholder Information - The company reported a total of 18,527 common shareholders at the end of the reporting period[8] - The largest shareholder, Wu Zhimin, holds 47.50% of the shares, totaling 28,000,000 shares[8] - Shareholders' equity attributable to the parent company rose by 149.88% to ¥1,173,028,116.32, also due to the public issuance of A-shares[7] - The company has a total of 44,971,152 restricted shares at the end of the reporting period, with no new restricted shares added during the period[11] Contracts and Future Plans - The company signed a three-year sales contract framework with BIOCARE TECHNOLOGY COMPANY LIMITED for the sale of extracorporeal circulation bloodline products in the Asia-Pacific and Europe regions[12] - The company aims to expand its production capacity and enhance market competitiveness through the successful implementation of its fundraising projects[13] - The future sales volume under the contract with BIOCARE TECHNOLOGY is subject to uncertainty due to market competition and industry policies[12] Stock Market Activity - The company officially listed on the Shenzhen Stock Exchange on April 7, 2022, raising a net amount of CNY 694.56 million, primarily for the construction of production projects and a comprehensive R&D center[13]
天益医疗(301097) - 2022 Q1 - 季度财报